|14. Switch to a different TNFi biologic + MTX over switching to a different TNFi biologic monotherapy (PICO 33)|Very low|
|Conditional recommendation based on very-low-quality evidence; may consider switching to a different TNFi biologic monotherapy if the patient has demonstrated MTX-associated adverse events, prefers to receive fewer medications, or perceives MTX as a burden.|Conditional recommendation based on very-low-quality evidence; may consider switching to a different TNFi biologic monotherapy if the patient has demonstrated MTX-associated adverse events, prefers to receive fewer medications, or perceives MTX as a burden.|
|15. Switch to an IL-17i biologic monotherapy over an IL-17i biologic and MTX combination therapy (PICO 35)|Very low|